shares of Editas Medicine Inc (EDIT) on
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 133 full-time employees. The company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The company operates through developing and commercializing genome editing technology segment. The company is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. The company is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).